Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


15 enero 2021

Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis

Richard G. Jung, Trevor Simard, Christopher Kovach, Kelsey Flint, Creighton Don, Pietro Di Santo, Marianna Adamo, Luca Branca, Francesca Valentini, Tomás Benito-González, Felipe Fernández-Vázquez, Rodrigo Estévez-Loureiro, Alessandra Berardini, Nicolina Conti, Claudio Rapezzi, Elena Biagini, Simon Parlow, Risa Shorr, Amos Levi, Ana Manovel, Rosa Cardenal-Piris, Jose Diaz Fernandez, Mony Shuvy, Dan Haberman, Alessandra Sala, Mohamad A. Alkhouli, Claudia Marini, Marta Bargagna, Davide Schiavi, Paolo Denti, Sinisa Markovic, Nicola Buzzatti, Vincent Chan, Mark Hynes, Thierry Mesana, Marino Labinaz, Federico Pappalardo, Maurizio Taramasso, and Benjamin Hibbert

Objectives The aim of this study was to evaluate the outcome of transcatheter mitral valve repair (TMVr) in patients with cardiogenic shock and significant mitral regurgitation (MR).

15 enero 2021

COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation

Marianna Adamo, Francesca Fiorelli, Bruno Melica, Renzo D’Ortona, Laura Lupi, Cristina Giannini, Gualter Silva, Claudia Fiorina, Luca Branca, Ermanna Chiari, Giuliano Chizzola, Paolo Spontoni, Cláudio Espada Guerreiro, Salvatore Curello, Anna Sonia Petronio, and Marco Metra

The aim of this study was to evaluate whether fulfilling COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) criteria identifies patients with better outcomes after MitraClip treatment for secondary mitral regurgitation (SMR).

15 enero 2021

Cardiopulmonary Hemodynamic Profile Predicts Mortality After Transcatheter Tricuspid Valve Repair in Chronic Heart Failure

Thomas J. Stocker, Helene Hertell, Mathias Orban, Daniel Braun, Karl-Philipp Rommel, Tobias Ruf, Geraldine Ong, Michael Nabauer, Simon Deseive, Neil Fam, Ralph S. von Bardeleben, Holger Thiele, Steffen Massberg, Philipp Lurz, and Jörg Hausleiter

Objectives This study was designed to assess hemodynamic changes in response to transcatheter tricuspid valve edge-to-edge repair (TTVR) and to identify hemodynamic predictors associated with mortality.

15 enero 2021

Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes

Charles J. Davidson, D. Scott Lim, Robert L. Smith, Susheel K. Kodali, Robert M. Kipperman, Mackram F. Eleid, Mark Reisman, Brian Whisenant, Jyothy Puthumana, Sandra Abramson, Dale Fowler, Paul Grayburn, Rebecca T. Hahn, Konstantinos Koulogiannis, Sorin V. Pislaru, Todd Zwink, Michael Minder, Abdellaziz Dahou, Shekhar H. Deo, Prashanthi Vandrangi, Florian Deuschl, Ted E. Feldman, William A. Gray, and on behalf of the Cardioband TR EFS Investigators

Objectives The study reports for the first time the 30-day outcomes of the first U.S. study with the Cardioband tricuspid valve reconstruction system for the treatment of functional tricuspid regurgitation (TR).

15 enero 2021

Biventricular Physiology of Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Edge-to-Edge Repair

Stephan Blazek, Matthias Unterhuber, Karl-Philipp Rommel, Maximilian von Roeder, Karl-Patrik Kresoja, Tobias Kister, Christian Besler, Karl Fengler, Marcus Sandri, Ingo Daehnert, Holger Thiele, and Philipp Lurz

Objectives The study sought to assess the acute hemodynamic effects of iatrogenic atrial septal defect (iASD) closure following transcatheter mitral valve edge-to-edge repair (TMVR).

15 enero 2021

Successful MitraClip Therapy for Atrial Functional Mitral Regurgitation With Severe Mitral Annular Calcification

Hiroki Ikenaga, Tasuku Higashihara, Kiho Itakura, Hiroto Utsunomiya, Yukihiro Fukuda, Taiichi Takasaki, Shinya Takahashi, and Yukiko Nakano

An 80-year-old woman had severe atrial functional mitral regurgitation (MR) and multiple admissions for heart failure. Computed tomography demonstrated severe mitral annular calcification (MAC) involving more than two-thirds of the annulus (Figure 1A, yellow arrows). Transesophageal echocardiography showed bulky calcification protruding from the posterior annulus (Figure 1B, yellow arrows). The posterior mitral leaflet was restricted but not calcified severely (Figure 1B, blue arrows). Because of very high surgical risk, the patient was offered MitraClip therapy (MitraClip NT, Abbott Vascular, Santa Clara, California). A clip arm was opened at an angle of almost 180° to insert the arm between the posterior leaflet and protruding MAC (Figure 1Ca). The grasp was performed centrally with careful attention to grasp both leaflets adequately and avoid leaflet tear (Figure 1Cb). Insertion length of the posterior leaflet was 6 mm. With a single clip, MR was reduced from severe to mild (Figure 1Cc, Video 1). Post-procedure, pulmonary vein flow was improved from diastolic wave dominant to systolic wave dominant (Figure 1Cd). The patient’s status improved, and echocardiography 1 month after the procedure showed mild to moderate MR.

15 enero 2021

Serial Imaging Assessment of Clinical Valve Thrombosis After Transcatheter Aortic Valve Replacement With LOTUS Edge

Noriaki Moriyama, Shohei Yokota, Koki Shishido, Futoshi Yamanaka, Eiji Koyama, Takahiro Murai, Takahiro Hayashi, Takashi Yamada, Yuka Mashimo, Hiroaki Yokoyama, Masashi Yamaguchi, Tamiharu Yamagishi, Kazuki Tobita, Shingo Mizuno, Yutaka Tanaka, Masato Murakami, Saeko Takahashi, and Shigeru Saito

An 87-year-old woman with symptomatic severe aortic stenosis underwent transcatheter aortic valve replacement with a 23-mm LOTUS Edge (Boston Scientific, Natick, Massachusetts) (Video 1). At discharge, she was asymptomatic, and device success was achieved (mean pressure gradient 12.6 mm Hg, no paravalvular regurgitation); she was prescribed only oral aspirin 100 mg. After initial improvement, the patient became breathless (New York Heart Association [NYHA] functional class III) at 30-day follow-up with a prolonged ejection systolic murmur. Transthoracic echocardiography (TTE) showed a considerable rise in aortic transvalvular gradient (45.9 mm Hg). Multidetector computed tomography demonstrated hypoattenuated leaflet thickening (HALT) of all 3 cusps with severely reduced leaflet motion (RELM) of all 3 leaflets (Figures 1A to 1D). Therefore, the patient was diagnosed with clinical valve thrombosis. After hospitalization, systematic anticoagulation (intravenous heparin, activated partial thromboplastin time 45 to 60 s, followed by oral vitamin K antagonist [VKA], international normalized ratio 2.5 to 3.0) was immediately initiated. Fourteen days after anticoagulation therapy, TTE showed improved hemodynamic status (mean pressure gradient 20.3 mm Hg) with significant resolution of HALT and RELM on multidetector computed tomography (Figures 1E to 1H). The patient was discharged from the hospital on an oral VKA with NYHA functional class II symptoms. At 60-day follow-up, her shortness of breath had improved to NYHA functional class I, and imaging examinations revealed normal function of the LOTUS Edge valve (mean pressure gradient 13.0 mm Hg) without trileaflet HALT and RELM (Figures 1I to 1L). During this treatment period, no signs of thrombus embolization was observed. Regular follow-up was planned every 3 months with TTE as needed, with permanent VKA therapy.

15 enero 2021

Transcatheter Mitral Valve Repair With Leaflet-to-Ring Technique in the Presence of a Radiolucent Prosthetic Ring

Neal Duggal, Matthew Romano, Daniel Menees, Stanley J. Chetcuti, Steven F. Bolling, and Gorav Ailawadi

A 66-year-old man presented with recurrent heart failure (New York Heart Association functional class III) and severe mitral regurgitation (MR) in the setting of previous surgical repair involving P2 resection and placement of a 38-mm Cosgrove Edwards annuloplasty ring. We present a case of a MitraClip (Abbott Vascular, Santa Clara, California) affixing the native anterior leaflet to the annuloplasty ring under 2-dimensional and real-time 3-dimensional (3D) multiplanar reconstruction (MPR) with transesophageal echocardiography.

15 enero 2021

Synergistic Effect of 2 Transcathehttps://www.jacc.org/doi/10.1016/j.jcin.2020.10.006ter Tricuspid Valve Treatment Modalities

Noé Corpataux, Nicolas Brugger, Mirjam G. Winkel, Thomas Pilgrim, Lars Englberger, Stephan Windecker, Lukas Hunziker, and Fabien Praz

An 81-year-old patient with multivalvular heart disease presented with symptomatic severe secondary mitral regurgitation 18 years after mechanical aortic valve replacement. Due to age and previous open-heart surgery, the patient was considered at increased risk for reoperation on multiple valves (EuroSCORE II 7.2%). He underwent uneventful implantation of 2 MitraClips (Abbott Laboratories, Abbott Park, Illinois) in the mitral position with sustained reduction of mitral regurgitation to grade 2+. Two years later, symptoms of right heart failure and worsening dyspnea (New York Heart Association [NYHA] functional class III) ensued owing to severe secondary tricuspid regurgitation (TR) (Figures 1A and 1B, Videos 1 and 2). Due to the predominant anteroseptal jet localization, bicuspidization of the valve by means of implantation of 2 MitraClip XTR was performed with reduction of TR to grade 2+ (Figures 1C to 1E, Videos 3 and 4). After initial clinical improvement, symptoms of worsening dyspnea (NYHA functional class III) and peripheral edema recurred 10 months later. Transesophageal echocardiography revealed recurrent severe central TR related to progressive tricuspid annulus dilatation (4.9 to 5.4 cm) (Figure 2A, Videos 5 and 6) despite good clip attachment. Several reasons may explain the observed disease progression, including elevated pulmonary vascular resistance, persisting volume overload (residual TR) or further decrease of the right ventricular function in the context of past cardiotomy. After assessment of anatomic eligibility, transcatheter tricuspid annuloplasty using the Cardioband system (Edwards Lifesciences, Irvine, California) was selected due to its ability to reverse annular dilatation and was performed 12 months after tricuspid edge-to-edge repair (Figures 2B and 2C). The tricuspid annulus area was cinched from 22.3 cm2 to 18.3 cm2 with subsequent TR reduction to mild (Figure 2D, Video 7). No adverse events occurred, and the patient was discharged home 2 days after the procedure.

15 enero 2021

Amplatzer Vascular Plug III and Interclip Mitral Regurgitation: A Good Alternative When Another Clip Doesn’t Fit

Laura Sanchis, Pedro L. Cepas, Pedro R. Pérez Fuentes, Albert Carramiñana, Eduardo J. Flores, Marta Farrero, Ander Regueiro, Manel Sabaté, Marta Sitges, and Xavier Freixa

A 60-year-old patient presented with symptomatic residual severe mitral valve regurgitation (MR). An emergent percutaneous mitral valve repair with a MitraClip (Abbott Vascular, Santa Clara, California) in the context of acute papillary muscle rupture after ST-segment elevation myocardial infarction had been performed 1 year before. In the initial procedure, 2 central MitraClip NTR devices were implanted; residual MR seemed to be moderate but was difficult to assess because of rapid ventricular response to atrial fibrillation. Considering the critical clinical situation, the relevant reduction of MR (from massive to moderate), and the challenging anatomy, no additional clips were implanted. After the intervention, the patient was discharged from the hospital, but progressive clinical worsening with 3 hospital admissions for heart failure occurred within 1 year. Control echocardiography showed severe residual MR (Figure 1, Videos 1 and 2) with a regurgitant jet originating between the two implanted clips. As shown in Figure 1, Video 3, both clips described a triangular area, as the posterior prolapsing leaflet was short at this level and could not be grasped. After a heart team discussion, a new percutaneous mitral valve repair was proposed. The initial strategy was the implantation of a third clip between the previous 2 clips, but insufficient space at the level of the anterior leaflet precluded this approach (Figure 1). Given the triangular shape of the residual orifice, an Amplatzer Vascular Plug (AVP) III (14 × 5 mm; Abbott Vascular) (Videos 4, 5, 6, and 7) was implanted, effectively reducing the MR to mild. At 3 months, the patient had no congestive signs and mild residual MR.

15 marzo 2021

Prognostic Links Between OCT-Delineated Coronary Morphologies and Coronary Functional Abnormalities in Patients With INOCA

Kensuke Nishimiya, Akira Suda, Kento Fukui, Kiyotaka Hao, Jun Takahashi, Yasuharu Matsumoto, Kiyoto Mitsuishi, Tasuku Watanabe, Kazuma Ohyama, Jun Sugisawa, Satoshi Tsuchiya, Koichi Satoh, Tomohiko Shindo, Shigeo Godo, Yoku Kikuchi, Takashi Shiroto, Satoshi Yasuda, and Hiroaki Shimokawa

Objectives Whether there are prognostic links between coronary morphologies and coronary functional abnormalities was examined in ischemia and nonobstructive coronary artery disease (INOCA) patients.

15 marzo 2021

Invasive Approaches in the Management of Cocaine-Associated Non–ST-Segment Elevation Myocardial Infarction

Shilpkumar Arora, Rahul Jaswaney, Chinmay Jani, Zachary Zuzek, Samarthkumar Thakkar, Mohini Patel, Sidakpal S. Panaich, Byomesh Tripathi, Nirav Arora, Richard Josephson, Mohammed Najeeb Osman, Brian D. Hoit, David Zidar, and Mehdi H. Shishehbor

Objectives The aim of this study was to determine the impact of invasive approaches and revascularization in patients with cocaine-associated non–ST-segment elevation myocardial infarction (NSTEMI).

15 marzo 2021

Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial

Thomas Pilgrim, Olivier Muller, Dik Heg, Marco Roffi, David J. Kurz, Igal Moarof, Daniel Weilenmann, Christoph Kaiser, Maxime Tapponnier, Sylvain Losdat, Eric Eeckhout, Marco Valgimigli, Peter Jüni, Stephan Windecker, and Juan F. Iglesias

Objectives The aim of this study was to investigate the safety and efficacy of biodegradable-polymer sirolimus-eluting stents (BP-SES) compared with durable-polymer everolimus-eluting stents (DP-EES) in patients with ST-segment elevation myocardial infarction (STEMI).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.